Is West Pharmaceutical Services (WST) Cheap Following Its Recent Run Up?

West Pharmaceutical Services (WST) drew fresh attention after recent share price moves, with the stock last closing at US$346.23. Investors are weighing that level against the business profile and recent return history.

Recent trading suggests momentum for West Pharmaceutical Services is still broadly positive. The 90 day share price return is 5.29% and the year to date share price gain is 25.26%, while the 1 year total shareholder return of 37.01% contrasts with a weaker 3 year and 5 year total shareholder return record, hinting that sentiment has strengthened more recently than over the longer stretch.

Capitalize on the renewed momentum in West Pharmaceutical Services by comparing it with a hand picked group of 16 high quality undiscovered gems that share strong fundamentals but still fly under most radars.

For West Pharmaceutical Services, the recent climb in returns could point to renewed faith in the underlying drug packaging franchise, or it could simply reflect hotter sentiment around the stock. How does the current valuation stack up against that backdrop?

Most Popular Narrative: 14.3% Undervalued

On the most followed narrative, West Pharmaceutical Services screens below its estimated fair value of $404 against the last close at $346.23, which puts a clear spotlight on the earnings and cash flow story behind that gap.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The anticipated high single-digit growth rate for Biologics HVP components in the second half of 2025, despite initial destocking challenges, shows potential for revenue acceleration and earnings improvement.

Read the complete narrative.

Want to see what justifies that premium fair value on West Pharmaceutical Services? The narrative leans on steady top line expansion, thicker margins, and a future earnings base that assumes a still rich P/E multiple. Curious which specific growth paths and profitability targets need to line up to keep that $404 figure intact.

Result: Fair Value of $404 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the story for West Pharmaceutical Services can change quickly if GLP 1 demand softens or if tariffs and pricing pressure squeeze margins more than expected.

Find out about the key risks to this West Pharmaceutical Services narrative.

Another View on West Pharmaceutical Services Valuation

The fair value narrative presents West Pharmaceutical Services as 14.3% undervalued at $404 versus the $346.23 share price. The market ratio perspective looks different. The current P/E of 43.1x is higher than the 23.4x fair ratio, the 35.6x global Life Sciences average, and the 38.4x peer group level. This points to a valuation that may be vulnerable if sentiment cools. Which signal do you treat as more important: the cash flow based fair value or the elevated earnings multiple?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing the mixed signals around West Pharmaceutical Services and wondering what matters most for you right now? Move quickly, stress test the numbers yourself, then see how those potential upsides stack up in the 2 key rewards.

Looking for more investment ideas beyond West Pharmaceutical Services?

If West Pharmaceutical Services has your attention, do not stop there. Broaden your watchlist now so you are not chasing opportunities after they have already moved.

• Target value up front by scanning a focused group of 31 high quality undervalued stocks that combine solid fundamentals with prices that still look restrained.
• Prioritize resilience by reviewing a 11 resilient stocks with low risk scores that emphasizes stronger balance sheets and calmer risk profiles when markets get choppy.
• Hunt for financially robust outliers through a list of solid balance sheet and fundamentals (23 results) to spot companies that may handle shocks better than the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com